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ABSTRACT
Despite aggressive treatment for localized cancer, prostate cancer (PC) remains 
a leading cause of cancer-related death for American men due to a subset of patients 
progressing to lethal and incurable metastatic castrate-resistant prostate cancer 
(CRPC). Organ-confined PC is treated by surgery or radiation with or without androgen 
deprivation therapy (ADT), while options for locally advanced and disseminated PC 
include radiation combined with ADT, or systemic treatments including chemotherapy. 
Progression to CRPC results from failure of ADT, which targets the androgen receptor 
(AR) signaling axis and inhibits AR-driven proliferation and survival pathways. The 
exact mechanisms underlying the transition from androgen-dependent PC to CRPC 
remain incompletely understood. Reactivation of AR has been shown to occur in CRPC 
despite depletion of circulating androgens by ADT. At the same time, the presence of 
AR-negative cell populations in CRPC has also been identified. While AR signaling has 
been proposed as the primary driver of CRPC, AR-independent signaling pathways 
may represent additional mechanisms underlying CRPC progression. Identification 
of new therapeutic strategies to target both AR-positive and AR-negative PC cell 
populations and, thereby, AR-driven as well as non-AR-driven PC cell growth and 
survival mechanisms would provide a two-pronged approach to eliminate CRPC cells 
with potential for synthetic lethality. In this review, we provide an overview of AR-
dependent and AR-independent molecular mechanisms which drive CRPC, with special 
emphasis on the role of the Jak2-Stat5a/b signaling pathway in promoting castrate-
resistant growth of PC through both AR-dependent and AR-independent mechanisms.
INTRODUCTION
Recent epidemiological data identifies prostate 
cancer (PC) as the most common non-cutaneous cancer 
and the second-leading cause of cancer-related death 
among males in the United States following lung 
cancer [1]. According to the American Cancer Society, 
approximately 180,000 new cases of PC are diagnosed 
and 26,000 men, or 1 in 39, die of PC each year [1]. The 
clinical course of PC is heterogeneous, ranging from 
indolent to rapidly progressive and fatal. While the five-
year survival rate for localized PC is close to 100% due 
to the availability of curative treatments, some patients 
experience cancer progression to metastatic castrate-
resistant prostate cancer (CRPC), which is currently 
incurable and carries a poor prognosis (reviewed in [2-4]). 
Although the recent U.S. Food and Drug Administration 
                  Review
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(FDA) approval of numerous therapeutic agents for 
CRPC is promising, an unmet need still exists for the 
development of rational biomarkers and novel treatment 
strategies to improve survival.
 Prior to 2010, the chemotherapeutic taxane 
docetaxel (Taxotere®) was the only drug demonstrated 
to improve survival of CRPC patients in comparison 
to palliative chemotherapy with mitoxantrone 
(Novantrone®), increasing median overall survival from 
16.3 to 19.2 months [5, 6]. In the last several years, 
there has been an influx of new therapies mainly due to 
improved understanding of CRPC biology [4, 7]. These 
promising drugs have positively altered the therapeutic 
landscape of CRPC, but emerging resistance mechanisms 
have already been described for most of these agents 
(reviewed in [8-11]).
The therapeutic agents receiving FDA approval for 
treatment of advanced PC in the past five years include 
1) abiraterone (Zytiga®; approved 2011), 2) enzalutamide 
(Xtandi®; approved 2012), 3) cabazitaxel (Jevtana®; 
approved 2010), 4) sipuleucel-T (Provenge®; approved 
2010) and 5) Alpharadin (Xofigo®; approved 2013) 
(reviewed in [4, 12-14]). Abiraterone is a small-molecule 
inhibitor of cytochrome P450 17A1 (CYP17A1), an 
enzyme required for both adrenal and intratumoral de 
novo biosynthesis of androgens [15]. Enzalutamide is 
a second-generation antiandrogen and acts as a pure 
antagonist with no agonist activity [16, 17]. Cabazitaxel 
is a third-generation chemotherapeutic of the taxane 
class, which demonstrated superiority to palliative 
mitoxantrone-based chemotherapy in the post-docetaxel 
metastatic CRPC setting, although the use of the drug 
has been hampered by hematological adverse events, 
most notably febrile neutropenia [18]. Sipuleucel-T is 
an autologous cellular immunotherapy, also referred to 
as a therapeutic cancer vaccine, designed to generate an 
immune response against PC cells expressing prostatic 
acid phosphatase [19, 20]. Alpharadin is a radioisotope-
containing radium-223 dichloride, a nuclide which emits 
alpha particles, that allows for targeting of PC bone 
metastases with short-range, high-energy alpha radiation 
[21]. Clinical trials that investigate the optimal sequence 
[7, 14] and combinations of these agents in advanced 
PC to minimize side effects and exploit synergistic 
mechanisms are needed. Most importantly, novel agents 
which can be deployed to impose synthetic lethality [22, 
23] or applied as second- or third-line treatments [24] in 
the setting of resistance to current therapies need to be 
identified and further developed. The clinical limitations 
of a narrow focus on androgen receptor (AR) as the sole 
therapeutic target in PC have been increasingly recognized 
as resistance to any agents targeting AR is inevitable 
[25-27]. Investigational approaches using combination 
therapy with pharmacological agents directed against AR 
and other molecular targets, in addition to AR-negative 
cells, in advanced PC may prove to be critical to enhance 
efficacy and delay onset of resistance to agents targeting 
AR in PC.
THERAPEUTIC TARGETING OF AR IN 
PROSTATE CANCER GROWTH
Similar to normal prostate, PC cells require 
androgens for continued growth [28]. The requirement 
for androgens is effectively exploited through the use of 
ADT as a first-line therapy for advanced PC (reviewed in 
[29-31]). AR, a member of the steroid hormone group of 
nuclear receptors which includes estrogen receptor (ER), 
progesterone receptor (PR) and mineralocorticoid receptor 
(MR), functions as a ligand-dependent transcription 
factor. Binding of androgen ligands, such as testosterone 
and the more potent dihydrotestosterone (DHT), induces 
a conformational change in AR that allows for nuclear 
translocation and induction of androgen-responsive gene 
expression supporting growth and viability of prostate 
cells (reviewed in [32-36]). Mechanistically, AR inhibition 
induces both cell cycle arrest and apoptosis of PC cells 
[37-41]. Expression of AR is found in primary PC and 
continues to be detectable throughout progression to 
CRPC [42, 43]. 
ADT by means of surgical or pharmacological 
castration, the latter in the form of luteinizing hormone-
releasing hormone (LHRH) / Gonadotropin-releasing 
hormone (GnRH) agonists (e.g. leuprorelin (Lupron®); 
goserelin (Zoladex®)) reduces serum testosterone levels 
by 90-95%. This robust decrease in serum androgens is 
dampened by the fact that intraprostatic levels of DHT 
have been reported to decline by only about 50% [44]. The 
stimulus from the residual intraprostatic DHT and other 
androgens can be blocked by addition of an antiandrogen 
drug to produce combined androgen blockade (CAB) 
[4, 12, 45, 46]. First-generation antiandrogens such as 
flutamide and bicalutamide have been used clinically for 
decades and function as AR antagonists by competitive 
inhibition of androgen binding to AR [4, 12, 45, 46]. In 
the case of bicalutamide, it also promotes recruitment 
of AR corepressors which contributes to inhibition of 
AR transcriptional activity [47]. The second-generation 
antiandrogen enzalutamide, designed to bind the AR 
ligand-binding domain (LBD), induces a conformational 
change in AR that prevents AR nuclear translocation to 
a greater extent than first-generation agents [16, 17]. In 
contrast to the use of LHRH/GnRH agonists alone, the 
addition of antiandrogens should theoretically prevent 
residual intraprostatic DHT from binding to AR. However, 
meta-analyses of clinical trials comparing CAB vs. 
LHRH/GnRH agonist monotherapy for advanced PC have 
demonstrated only a modest benefit in overall survival, 
often outweighed by added toxicity and decreased quality 
of life [48-50].
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PROGRESSION OF PROSTATE CANCER 
TO CASTRATE-RESISTANT DISEASE 
PC is considered castrate resistant during ADT with 
castrate levels of serum testosterone (<50 ng/dL) if it 
fullfils one or more of the following criteria: 1) a rise of 
prostate-specific antigen (PSA) serum levels (biochemical 
progression), 2) development of symptoms in the presence 
of pre-existing cancer (clinical progression) or 3) detection 
of new metastatic lesions on imaging (radiographic 
progression) [51, 52]. CRPC has historically been referred 
to by several names, including “hormone-refractory” and 
“androgen-independent” PC [53]; however, the preferred 
terminology is “castrate-resistant” in recognition of 
intracrine androgen production which is at least partially 
responsible for resistance to ADT [54, 55]. CRPC presents 
as a spectrum of disease, ranging from asymptomatic 
rising PSA levels without evidence of metastasis to 
multiple distant metastases with debilitating cancer-related 
constitutional symptoms.
The mechanisms driving progression from 
androgen-dependent PC to CRPC are still largely unclear. 
Continued AR signaling, despite depletion of circulating 
androgens and AR blockade, is thought to be central to 
the development of CRPC [56, 57]. Reactivation of AR 
transcriptional activity has been attributed to various 
mechanisms, yet no single mechanism has been reliably 
shown to account completely for progression to CRPC 
in experimental models or clinical patients. The majority 
of research efforts have sought to understand how AR 
signaling is restored in CRPC, but a growing number of 
studies highlight mechanisms operating outside the AR 
signaling axis, which may substantially contribute to the 
development of CRPC. Figure 1 provides a summary of 
the most widely investigated mechanisms thought to drive 
CRPC.
AR-DEPENDENT MOLECULAR 
MECHANISMS DRIVING CASTRATE-
RESISTANT PROSTATE CANCER
AR gene amplification and overexpression
One mechanism of AR reactivation in CRPC is 
via increased expression of AR, which may be achieved 
through genomic amplification of the AR locus or 
upregulation of AR protein levels. Early work using 
patient-matched clinical specimens indicated that 
approximately 30% of CRPC tumors harbored high-level 
Figure 1: Molecular mechanisms driving CRPC. Development of CRPC has been attributed to numerous potential molecular 
mechanisms, including: 1) somatic mutations of AR resulting in increased affinity for ligands; 2) amplification of the AR gene locus; 3) 
intracrine biosynthesis of androgens in prostate cancer cells from adrenal steroids and cholesterol; 4) expression of constitutively active, 
ligand-independent AR splice variants; 5) non-canonical activation of AR by protein kinase signaling pathways in the absence of ligand 
by receptor tyrosine kinases (RTK); 6) AR-independent mechanisms operating outside of the AR signaling axis which promote castrate-
resistant growth of prostate cancer.
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AR gene amplification as demonstrated by fluorescence 
in situ hybridization (FISH), in comparison to none 
of the androgen-dependent primary tumors [58, 59]. 
Increased AR expression can sensitize PC cells to sub-
physiological levels of androgen [60] and overcome 
inhibition by antiandrogens such as bicalutamide [61]. 
PC cells which overexpress AR are capable of accessing a 
greater number of binding sites on chromatin, generating 
an altered AR transcriptome [62]. In one report, cDNA 
microarray analysis of CRPC xenograft tumors found that 
the only change consistently associated with antiandrogen 
resistance was a modest increase in AR mRNA levels [63].
Somatic AR mutations
Somatic AR mutations may occur selectively in 
response to androgen deprivation, although the exact 
frequency of AR mutations in PC remains unknown. A 
review of 27 clinical studies found that AR mutations in 
androgen-dependent tumors ranged from 2-25%, while 
the incidence in CRPC tumors was slightly higher at 10-
40% [64]. Additional work has identified the AR LBD as 
a mutational hotspot, with more recent studies placing 
the incidence of AR LBD point mutations in CRPC at 
~15-20% [65-68]. Several gain-of-function AR LBD 
mutations which confer hypersensitivity to androgens or 
broaden ligand specificity have been characterized. Two 
well-known examples are AR-T877A and AR-W741C, 
originally described in LNCaP cells, which convert the 
antiandrogens flutamide and bicalutamide to partial 
agonists, respectively [69, 70].
Resistance to the second-generation antiandrogens 
enzalutamide (formerly MDV3100) and apalutamide 
(formerly ARN-509) was shown to be conferred by the 
novel AR LBD mutation F876L (alternatively reported 
as F877L in a different genomic build) in in vitro and in 
vivo models of PC [25-27]. Moreover, AR-F876L was 
also detected circulating as cell-free tumor DNA in the 
serum of patients who had received apalutamide as part of 
a phase I clinical trial [26]. AR-F876L repositions the co-
activator docking helix 12 of AR, promoting an antagonist-
to-agonist switch of enzalutamide and apalutamide [25-
27]. However, the overall contribution of AR-F876L to 
clinical resistance to second-generation antiandrogens 
remains to be determined; a genomic landscape study of 
150 men with metastatic CRPC using next-generation 
sequencing did not detect the mutation, despite some 
patients previously receiving enzalutamide [68].
Analysis of plasma from patients with metastatic 
CRPC for circulating cell-free tumor DNA detected 
several AR LBD mutations associated with abiraterone 
resistance, including AR-T878A and AR-L702H [71, 
72]. In one such study, emergence of AR-T878A and 
AR-L702H was observed in 13% of CRPC tumors 
progressing on abiraterone, while total AR copy number 
remained unchanged pre- and post-treatment with 
abiraterone [71]. Mechanistically, these AR LBD mutants 
were demonstrated to sensitize AR to activation by 
progesterone (T878A) [73] and glucocorticoids (L702H) 
[74], circumventing the effects of CYP17A1 inhibition on 
AR signaling. Interestingly, it is necessary for abiraterone 
to be administered concurrently with the glucocorticoid 
prednisone to prevent the common adverse reaction 
of mineralocorticoid excess syndrome resulting from 
prolonged CYP17A1 blockade [74].
Prostate intracrine androgen biosynthesis
In the absence of circulating androgens produced 
by the testes, an alternative mechanism to activate AR 
signaling is through conversion of cholesterol and adrenal 
androgen precursors into testosterone and DHT in PC 
cells (reviewed in [75, 76]). It has been demonstrated 
that PC cells contain all components required for 
androgen biosynthesis, with many of the key enzymes 
being elevated in recurrent or metastatic tumors [77, 78]. 
Enzymes responsible for the conversion of cholesterol 
to androgen precursors (CYP17A1, HSDD3B2) and 
conversion of androgen precursors to testosterone and 
DHT (AKR1C3, SRD5A1/2) were shown to be elevated 
approximately 8-10 fold in metastatic PC [79]. Therefore, 
upregulation of the androgen production machinery 
may increase local androgen concentrations in CRPC, 
further facilitating reactivation of the AR signaling 
pathway. Production of androgen precursors, such as 
dehydroepiandrosterone (DHEA) and androstenedione, 
is blocked by abiraterone, which inhibits the enzymatic 
activity of the CYP17A1 enzyme [80, 81]. Other androgen 
biosynthesis inhibitors in clinical development are Ortonel 
(TAK-700), Galeterone (TOK-001/VN1/124-1) and VT-
464 [46]. However, several mechanisms of resistance to 
abiraterone were documented shortly after FDA approval, 
including elevated intratumoral levels of CYP17A1 [82] 
and gain-of-function mutations which sensitize AR to non-
androgen ligands [73, 74]; it remains to be seen whether 
these represent the primary means by which resistance 
develops to abiraterone.
AR splice variants (AR-Vs)
Constitutively active AR splice variants (AR-
Vs), generated through alternative gene splicing or 
rearrangement of the AR gene, have been increasingly 
studied as a contributor to castrate-resistant growth over 
the past several years. The expression of AR-Vs has 
now been well-documented in PC cell lines, xenograft 
tumors, and clinical PC samples [83-85]. The majority 
of AR-Vs have extensive truncation or exon skipping 
of the complete C-terminus, leading to loss of the AR 
LBD. AR-Vs, in which the bipartite nuclear localization 
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signal (NLS) contained in exons 3 and 4 is disrupted, 
were shown to be predominantly cytoplasmic in AR 
transactivation reporter assays [86]. However, other AR-
Vs contain both exons 3 and 4 and are thus capable of 
nuclear translocation and activation of AR target genes 
in a ligand-independent manner. A notable exception is 
AR-V7, the best characterized AR-V to date, which is 
constitutively active despite lacking a full NLS, through a 
mechanism yet to be fully determined [84, 86, 87].
Whether AR-Vs promote castrate-resistant 
growth of PC primarily by reactivating the normal AR 
transcriptome or generating an altered AR gene signature 
remains disputed. Although AR-Vs have been shown 
to be capable of activating canonical AR target genes 
such as KLK3 (encoding PSA), several studies have 
investigated whether AR-Vs can generate alternative gene 
signatures in CRPC cells [85-87]. One report found that 
the AR-V gene signature was largely independent of the 
transcriptional profile generated by full-length AR [88]. 
In contrast, the Dehm group found that AR-Vs, including 
AR-V7, preferentially bind the same canonical high-
affinity androgen response elements (AREs) engaged by 
full-length AR on a genome-wide scale [89]. Of note, the 
Dehm group developed a unique model, the R1-D567 
cell line, engineered to exclusively express constitutively 
active AR-Vs in the absence of full-length AR [89], 
while other investigators have used PC cell lines with 
heterogeneous expression of both full-length AR and AR-
Vs [85-87]. These findings suggest that AR-V genomic 
binding specificity and transcriptional output may be 
highly dependent on the experimental model selected and 
its particular cellular context.
The constitutive, ligand-independent activity of 
AR-Vs has substantial implications for treatment of 
CRPC. AR-V7 transcript and protein levels were found 
to be upregulated in clinical CRPC bone metastases and 
correlated with decreased survival rate after surgery [90]. 
In a more recent study, detection of AR-V7 in circulating 
tumor cells from enzalutamide- or abiraterone-treated 
patients was shown to be associated with therapeutic 
resistance to both agents [91]. AR-V7-positive patients 
treated with either enzalutamide or abiraterone were 
found to have lower PSA response rates, shorter PSA 
progression-free survival, shorter clinical or radiographic 
progression-free survival and shorter overall survival, 
compared to AR-V7-negative patients [91]. Based on the 
noted association, disruption of AR-V activity may be a 
means to prevent or reverse resistance to enzalutamide 
and abiraterone. Indeed, short-interfering RNA (siRNA)-
mediated knockdown of AR-V7 was shown to confer 
sensitivity to enzalutamide in CWR22Rv1 cells, which 
intrinsically express high levels of AR-V7 [92]. On 
the other hand, overexpression of AR-V7 in LNCaP 
cells negative for AR-Vs failed to confer resistance to 
enzalutamide in vitro or in vivo [86]. Further mechanistic 
work is therefore needed to determine the contribution of 
AR-V7 and other AR-Vs to development of resistance to 
enzalutamide and abiraterone.
A novel therapeutic strategy capable of inhibiting 
both full-length AR and AR-Vs relies on targeting of 
the AR N-terminus, which is conserved across all AR 
isoforms. EPI-001, a bisphenol A-derived small molecule 
antagonist, which covalently binds the AR N-terminal 
domain, was shown to block transcriptional activity of 
AR and several AR-Vs, including AR-V7 [93-96]. Based 
on the preclinical data, a prodrug formulation of the 
compound, EPI-506, is currently undergoing a Phase I/II 
clinical trial (NCT02606123) in CRPC patients previously 
treated with enzalutamide and/or abiraterone. Targeting of 
the AR N-terminus may prove to be a viable therapeutic 
approach for circumventing AR LBD-based deletions, 
which confer resistance to conventional antiandrogens and 
ligand-depleting agents such as abiraterone.
Non-canonical AR transactivation
Numerous growth factors, cytokines, and hormones 
have been implicated in the activation of AR when 
androgens are absent or present at sub-physiological 
concentrations [97]. Non-canonical induction of AR 
signaling has been linked to mechanisms which promote 
AR phosphorylation [98]. Insulin-like growth factor-1 
(IGF-1) was shown to induce AR transcriptional activity 
under androgen-deprived conditions in vitro, an effect 
which could be inhibited by bicalutamide [99]. Separately, 
it was reported that IGF-1-mediated AR activation 
required expression of β(1A) integrins, which facilitated 
functional interaction between the activated IGF-1 
receptor and AR, subsequently leading to AR-mediated 
anchorage-independent growth of PC [100]. Interleukin-6 
(IL-6) was shown to activate AR reporter gene constructs 
in DU145 PC cells and upregulate PSA secretion in 
LNCaP cells [101]. AR activation by IL-6 has been 
proposed to be mediated by both the Stat3 and MAPK 
signaling pathways in PC cells [102, 103]. Specifically, 
in the absence of androgens, IL-6 was shown to induce 
association of Stat3 and AR, followed by increased 
expression of AR-regulated genes [102].
Promotion of AR signaling in PC may also occur 
through loss of negative regulatory signals, which 
suppress AR function. This concept is supported by 
findings demonstrating that the cyclin D1b isoform of the 
widely studied cell cycle regulator does not possess AR 
inhibitory function attributed to the more common cyclin 
D1a isoform [104], and that cyclin D1b was found to be 
elevated in clinical PC specimens [105]. Additionally, a 
recent paper demonstrated that cyclin D1b cooperates with 
AR signaling to promote tumor cell growth and metastatic 
behavior of PC cells, partially by inducing expression 
of the pro-oncogenic transcription factor SNAI2 (Slug) 
[106]. In another example, loss or inactivation of the 
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retinoblastoma (Rb) tumor suppressor gene induced an 
E2F1-mediated increase in AR mRNA and protein levels, 
which promoted castrate-resistant growth and resistance to 
bicalutamide in PC cells [107].
Modulation of AR activity by receptor tyrosine 
kinases may contribute to progression of PC to castrate-
resistant cancer. Overexpression of Her2/neu (ErbB2) 
has been shown to enhance AR transcriptional activity in 
both the presence and absence of androgens, stimulating 
proliferation of LNCaP cells under both settings [108, 
109]. Moreover, Src kinase promoted AR transcriptional 
activity in castrate-resistant C4-2 cells [110]. In line with 
these findings, several other studies demonstrated that AR 
transcriptional activity was attenuated by protein kinase 
inhibitors [101, 111].
AR-INDEPENDENT MOLECULAR 
MECHANISMS DRIVING CRPC
AR-independent bypass pathways
While most research to date has focused on the 
continued importance of AR in CRPC, alternative 
signaling pathways supporting proliferation and 
survival of CRPC cells have been shown to be capable 
of completely bypassing AR [112-114]. Consequently, 
AR bypass pathways are not dependent on AR for their 
downstream effects and can theoretically remain active 
even in the absence of AR expression [112-114]. Sustained 
blockade of AR signaling may contribute to the selection 
of PC cell clones able to upregulate AR bypass pathways, 
conferring a castrate-resistant phenotype.
Several studies have investigated candidate genes 
which may support CRPC growth independently of AR. 
Whitworth and colleagues used an RNA interference 
(RNAi) phenotypic screen to profile 673 kinases and 
identify those which contributed most to castrate-
resistant growth of LNCaP cells under androgen-depleted 
conditions [112]. Moreover, expression of the anti-
apoptotic protein Bcl-2 was reported to be induced in PC 
xenograft tumors initially negative for Bcl-2 expression 
following castration of mice [115]. At the same time, 
inhibition of Bcl-2 using antisense oligonucleotides 
delayed onset of castrate resistance in an LNCaP xenograft 
tumor model [116]. Bcl-2 has been reported to be 
overexpressed in both mouse models of CRPC as well as 
clinical samples from CRPC patients [117, 118], although 
increased Bcl-2 expression is not strictly a prerequisite for 
progression to CRPC [118, 119].
A recent body of work supports the concept that the 
glucocorticoid receptor (GR) may be able to substitute for 
AR in binding to androgen response elements (AREs) and 
driving PC cell survival under certain circumstances [113, 
120, 121]. Chromatin immunoprecipitation followed by 
sequencing (ChIP-seq) and mRNA expression analysis 
indicated that these two steroid hormone receptors have 
highly overlapping cistrome and transcriptome profiles 
in PC [113, 120]. Furthermore, acquired resistance to 
enzalutamide in LNCaP cells and xenograft tumors 
correlated with upregulation of GR expression and was 
demonstrated to be dependent on GR for enzalutamide-
resistant growth [113]. Glucocorticoid-induced activation 
of GR in VCaP cells was also found to confer resistance 
to enzalutamide [113]. In the same study, PC xenograft 
tumors which developed resistance to the second-
generation antiandrogens enzalutamide and apalutamide 
showed a 27-fold higher expression of GR mRNA levels 
compared to controls [113]. Although research is ongoing, 
evidence thus far suggests that proliferation and survival 
signals may be able to bypass AR through GR in PC cells 
treated with antiandrogens, including second-generation 
agents. Whether other steroid hormone receptors, such 
as progesterone receptor (PR), contribute to AR bypass 
signaling remains to be determined.
AR-negative cell populations: prostate cancer 
stem-like cells
The cancer stem cell theory states that only a 
rare subpopulation of tumor cells possessing stem cell-
like properties, most notably unlimited self-renewal 
capacity, and multilineage differentiation, can initiate 
tumor formation [122]. The more general term “tumor-
initiating cells (TICs)” is also used interchangeably [123] 
with cancer stem-like cells, and refers to a population 
of cells within the original clinical cancer sample that 
has the ability and is critical for forming a tumor when 
xenotransplanted to immunodeficient mice [124]. In other 
words, the presence of TICs in patient-derived cancer 
samples and supportive growth environment for their 
proliferation in vivo determines the success rates of the 
tumor formation in mice [124]. Cancer stem cells are 
believed to be resistant to most therapies used to debulk 
tumors, harboring the ability to repopulate a tumor with 
therapy-resistant progeny more prone to metastasis 
(reviewed in [125, 126]). The gold standard for assessment 
of putative cancer stem-like cell populations is the 
capability of the cancer stem-like cells to generate serially 
transplantable xenograft tumors in immunodeficient mice 
that histopathologically resemble the parental tumor. Other 
surrogate assays/markers of cancer stem-like properties 
include cell surface markers, transcriptional profiles and 
tumor sphere-forming ability (reviewed in [127]).
Several putative populations of PC stem-like 
cells (PCSCs) have been reported in the literature, most 
commonly identified through fluorescence-activated cell 
sorting (FACS) of bulk tumor cell lines, xenograft tumors 
or clinical samples for stem-like cell surface markers. 
Reported marker profiles include CD44+/α2β1+/CD133+ 
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[128], TRA-1-60/CD151/CD166 [129], ALDH [130] 
and PSA−/lo [131], among others. While PC stem-like 
cells are positive for CD44 marker, the expression of the 
standard isoform of CD44 is typically lost in PC due to 
aberrant splicing[132]. Importantly, a number of reports 
have suggested that PCSCs are AR-negative or express 
very low levels of AR, predicting lack of responsiveness 
to antiandrogens and other therapies targeting the AR 
signaling axis. Patrawala and colleagues demonstrated 
that CD44+ PCSCs were negative for AR expression, 
as well as approximately 10-100x more tumorigenic in 
immunodeficient mice than CD44- non-PCSCs [133]. 
Moreover, putative CD44+/α2β1+/CD133+ PCSCs 
isolated from clinical PCs following prostatectomy were 
found to be AR-negative and exhibited a prostate basal cell 
phenotype [128]. More recent work supports enrichment 
of a basal cell gene expression profile in metastatic CRPC, 
establishing a link between expansion of a stem-like cell 
population and castrate resistance [134]. Collectively, 
this body of work suggests that residual AR-negative/low 
PCSCs may remain after androgen deprivation, potentially 
repopulating tumors with castrate-resistant tumor cells.
AR-negative cell populations: neuroendocrine 
prostate cancer cells
Interspersed within prostate epithelium are 
neuroendocrine (NE) cells, which can be identified 
by morphology under electron microscopy or through 
positive staining for chromogranin A, synaptophysin, 
neuron-specific enolase or other markers of NE 
differentiation [135]. These specialized cells secrete a 
variety of neuropeptides, such as bombesin, neurotensin, 
parathyroid hormone-related protein (PTHrP), serotonin 
and calcitonin, which are known to promote proliferation 
and survival of prostate adenocarcinoma cells [135]. In the 
normal prostate, NE cells constitute <1% of the total cell 
population and typically remain quiescent [135]. 
Neuroendocrine prostate cancer (NEPC) describes 
a heterogeneous group of tumors, including prostate 
adenocarcinoma with NE differentiation, adenocarcinoma 
with Paneth cell NE differentiation, carcinoid tumors, 
pure small cell carcinomas, pure large cell NE 
cancer and adenocarcinomas with mixed histologies 
[136]. Approximately 5-10% of primary prostate 
adenocarcinomas contain NE tumor cells, with greatest 
abundance in high-grade PCs [135, 137]. NEPC can be 
classified as de novo or treatment-related. NEPC arising 
de novo is a rare entity, typically constituting less than 
2% of all primary PCs and displays a high propensity for 
metastasis, limited treatment options and dismal prognosis, 
with most patients succumbing to the cancer within a year 
of diagnosis [138, 139]. Much more commonly, NEPC 
emerges in CR recurrent tumors in patients who have 
previously had androgen deprivation therapy for prostate 
adenocarcinoma (reviewed in [140-154]), suggesting that 
epithelial cells are able to transdifferentiate into NE cells 
and/or NE cells possess a proliferative advantage under 
androgen deprivation.
NEPC cells are negative for AR and PSA expression 
and highly proliferative [155]. Recent work by Beltran and 
colleagues [156] indicates divergent evolution of NEPC 
cells from one or more CRPC cells rather than linear 
clonal evolution. Moreover, NE differentiation in PC 
has been shown to be a predictive factor of unfavorable 
clinical outcome [147, 157-160]. Most importantly, 
emergence of NE differentiation during PC progression 
to CRPC has therapeutic implications. Specifically, 
molecular mechanisms driving AR-independent/negative 
NE cells in CRPC need to be identified for development 
of strategies to therapeutically target NE cell populations 
in CRPC.
The lack of AR expression in NEPC cells [135, 137] 
has led to efforts to determine the key signaling pathways 
that are dysregulated in these cells. Molecular profiling of 
NEPC revealed that deletion of RB1 and PTEN, mutations 
in TP53 and amplification of MYCN and Aurora kinase 
A (AURKA) are common in NE cells [161, 162]. Work 
from the Huang group demonstrated that mutant p53 
inactivates the IL-8/CXCR2/p53 signaling pathway 
which maintains NE cells in a quiescent state [163] and 
simultaneously results in AURKA overexpression, leading 
to hyperproliferation of NE cells [164]. Overexpression 
of N-Myc in LNCaP cells induced NE differentiation, 
downregulated AR levels and decreased AR target gene 
expression [162]. Moreover, the Witte group showed 
that aberrant N-Myc expression combined with activated 
AKT1 was sufficient to transform human prostate 
epithelial cells into NEPC with phenotypic features 
characteristic of metastatic CRPC in patients [165]. With 
the growing clinical use of abiraterone and enzalutamide 
to suppress AR signaling, NE differentiation may become 
an increasingly common resistance mechanism underlying 
castrate resistance.
JAK2-STAT5 SIGNALING PROMOTES 
GROWTH OF PROSTATE CANCER 
THROUGH AR-DEPENDENT AND 
AR-INDEPENDENT MOLECULAR 
MECHANISMS
Jak2-Stat5a/b signaling pathway in prostate 
cancer
In order to target AR-negative cell populations in 
CRPC and to impose an additional survival strain for 
AR-positive PC cells during ADT, identification of non-
AR therapeutic targets may provide novel treatment 
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strategies for CRPC. Stat5a/b are latent cytoplasmic 
proteins that function as both signaling molecules and 
nuclear transcription factors, which are critical for PC cell 
viability in vitro, in vivo and in patient-derived PCs ex vivo 
[166-174]. Two highly homologous isoforms, Stat5a and 
Stat5b (hereafter referred to as Stat5a/b), display over 90% 
amino acid identity and are encoded by genes juxtaposed 
on chromosome 17q21.2 [175].
In PC, Stat5a/b is predominantly activated by 
binding of prolactin (Prl) to the membrane-bound prolactin 
receptor (PrlR), which transmits signals through Jak2 
kinase [173, 176, 177]. In addition, Stat5a/b may also be 
activated by Src kinase or members of the EGF receptor 
family [178-180]. Prl is a polypeptide hormone whose 
actions are mediated by the PrlR, a non-kinase single-pass 
transmembrane receptor part of the class 1 hematopoietic 
cytokine receptor superfamily (reviewed in [181, 182]). 
Prl is primarily secreted by lactotroph cells of the anterior 
pituitary gland and carries out a wide variety of functions, 
including the well-known effect of stimulating lactation 
in females; circulating Prl is present in males, though at 
lower levels than in females (reviewed in [181, 182]). A 
large body of work provides evidence that Prl is expressed 
within the prostate epithelium and functions as a local 
growth factor in an autocrine/paracrine manner distinct 
from its endocrine mechanism [183-187]; (reviewed in 
[188]).
Signaling through the Jak2-Stat5a/b pathway is 
initiated upon Prl binding to PrlR and subsequent receptor-
associated Jak2 kinase activation by autophosphorylation. 
This leads to phosphorylation of cytoplasmic tyrosine 
residues of the cytokine receptor which serves as 
docking sites for Stat5a/b via binding of the Stat5a/b 
SH2 domain [189]. Stat5a/b monomers recruited to 
the receptor-tyrosine kinase complex are activated by 
tyrosine kinase-mediated phosphorylation at conserved 
C-terminal tyrosine residues (Stat5a: Y694, Stat5b: Y699) 
(reviewed in [190]). Phosphorylated Stat5a/b (pY694/699) 
monomers undergo homo- or heterodimerization, 
followed by nuclear localization of functional Stat5a/b 
dimers in an active, energy-dependent process directed 
by Ran-dependent nuclear import machinery [191, 192]. 
Specifically, a nuclear shuttling complex is formed by the 
chaperone protein MgcRacGAP, the small G protein Rac1 
and the carrier protein importin/karyopherin β1, which 
cooperate to translocate the Stat5a/b dimer from cytosol to 
nucleus [193]. Within the nucleus, Stat5a/b dimers bind to 
palindromic DNA consensus sequences (TTC(C/T)N(G/A)
Figure 2: Canonical Jak2-Stat5a/b signaling in prostate cancer cells and functional interaction with AR signaling. 
Various levels of inhibition are possible in the Stat5a/b signaling cascade to block Stat5a/b target gene expression, including targeting of 
cytokine receptor activation, Jak2 kinase-mediated phosphorylation, and Stat5a/b dimerization, DNA binding and transcriptional activity. 
Physical interaction between Stat5a/b and AR has been reported, providing a mechanistic basis for crosstalk between these two pathways, 
which results in reciprocal synergistic effects on nuclear localization and transcriptional activity. Depicted are known Stat5a/b target genes 
Bcl-xL and cyclin D1 and AR target gene PSA. Abbreviations: AR, androgen receptor; ARE, androgen response element; CYT, cytokine; 
CYTR, cytokine receptor; DHT, dihydrotestosterone; GAS, gamma-interferon activation sequence; GF, growth factor; HSP, heat shock 
protein; pY, phosphotyrosine.
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GAA), referred to as gamma-interferon activation (GAS) 
elements, to initiate transcription of Stat5a/b regulated 
genes [194-196]. Homodimers of Stat5a/b have equivalent 
specificity for binding palindromes spaced three base pairs 
apart [196, 197], while tetramers of Stat5a/b can bind 
tandem consensus and non-consensus GAS motifs spaced 
six base pairs apart [196]. The sequence of molecular 
events in the canonical Jak2-Stat5a/b signaling cascade 
leading to activation of Stat5a/b-regulated genes is shown 
in Figure 2.
Stat5a/b is a predictive biomarker and therapeutic 
target in prostate cancer
Over the last decade, numerous reports have 
supported the role of Stat5a/b in clinical progression of 
PC. Stat5a/b is constitutively active in human PC, but 
not in normal prostate epithelium [174]. Examination of 
the distribution of active Stat5a/b across 114 paraffin-
embedded clinical PC specimens of various histological 
grades revealed that active Stat5a/b was strongly 
associated with high-grade PC [173]. In a separate 
study, analysis of tissue microarrays derived from 357 
PC patients accompanied by 30-year clinical follow-up 
data found that high expression levels of active Stat5a/b 
were correlated with poorly differentiated, high-grade PC 
[172]. Importantly, active Stat5a/b status was predictive 
of early PC recurrence after initial treatment by radical 
prostatectomy or transurethral resection [172]. Active 
Stat5a/b was found to be an independent prognostic 
marker of early cancer recurrence not only in high-grade 
PC but also in intermediate grade PC [172]. Patients who 
had received androgen deprivation therapy prior to radical 
prostatectomy were more likely to display active Stat5a/b 
when compared to patients not receiving neoadjuvant 
therapy [172]. More recent work analyzing nuclear 
Stat5a/b expression levels in two cohorts of PC patients 
treated by radical prostatectomy or deferred palliative 
therapy showed that nuclear Stat5a/b was an independent 
prognostic marker for both cohorts [166]. Corroborating 
earlier work, high levels of nuclear Stat5a/b predicted 
increased risk of early cancer recurrence following radical 
prostatectomy in PCs of intermediate grade [166]. At the 
same time, active Stat5a/b predicted early PC-specific 
death in the deferred palliative therapy cohort [166]. In 
the cohort of PC patients treated by radical prostatectomy, 
each patient was represented by 10 tissue cores taken 
from different areas of the tumor. Interestingly, the 
presence of active Stat5a/b even in one of the 10 tissue 
cores already predicted likely cancer recurrence after 
radical prostatectomy [166], suggesting that those PCs 
with elevated nuclear Stat5a/b anywhere in the tumor may 
already have micrometastasized at the time of surgery. 
Further work demonstrated that the Stat5a/b gene locus 
is amplified in approximately 30% of CRPC metastases 
[198]. Similar to the presence of nuclear Stat5a/b 
Figure 3: Therapeutic targeting of Stat5a/b inhibits growth of prostate cancer through AR-dependent and AR-
independent mechanisms. Disruption of Stat5a/b signaling inhibits growth and viability of prostate cancer through two distinct 
mechanisms, serving as a potential dual strategy to eliminate prostate cancer cells. First, targeting of Stat5a/b inhibits the abilities of 
Stat5a/b to protect antiandrogen-liganded AR from proteasomal degradation and enhance AR signaling, including downstream molecular 
events such as AR nuclear localization, chromatin binding, and activation of target gene expression in prostate cancer cells. Second, 
targeting of Stat5a/b prevents the induction of AR-independent, Stat5a/b-regulated genes involved in proliferation and survival of prostate 
cancer cells.
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protein in specific areas of prostate tumor, Stat5a/b locus 
amplification was dispersed into groups of PC cells within 
the tumor tissue, as demonstrated by FISH of paraffin-
embedded tissue sections. It is important to note, however, 
that presence of specific areas with Stat5a/b gene locus 
amplification shown by FISH may not be detectable in 
analyses of RNA/DNA extracted from ground whole 
tissue specimens which include a mix of both epithelial 
and stromal components. Collectively, these findings 
indicate that Stat5a/b may provide a robust biomarker for 
recurrence of lethal PC after failure of first-line therapy for 
early stage cancer, warranting further investigation.
Stat5a/b promotes growth of prostate cancer cells 
and xenograft tumors
A substantial body of work supports the concept 
that Stat5a/b is highly critical for the viability of human 
PC cells in vitro and xenograft tumor growth in vivo. 
Inhibition of Stat5a/b by varied methods induced massive 
apoptotic death of PC cells in culture and suppressed the 
growth of xenograft tumors in nude mice [170, 171, 174, 
199]. Ahonen and colleagues provided the first evidence 
of Stat5a/b in promotion of PC growth [174]. Transduction 
of PC cells with adenovirus expressing dominant-
negative Stat5a/b lacking the transactivation domain, 
induced extensive apoptosis of PC cells, as determined 
by cell morphology, DNA fragmentation, caspase-3 and 
-9 activation, and cell viability assays [174]. Stat5a/b 
regulation of PC cell viability was further validated in 
the transgenic adenocarcinoma mouse prostate (TRAMP) 
model. In TRAMP-derived PC cell lines, use of an 
inducible carboxy terminal-truncated Stat5a/b construct 
to inhibit wild-type Stat5a/b activity led to decreased 
PC cell growth in soft agar and tumor formation in 
nude mice [200]. More recent studies further indicated 
a critical role of Stat5a/b in maintenance of PC viability, 
as inhibition of Stat5a/b by various methodological 
approaches (antisense oligonucleotides, RNA interference 
or adenoviral expression of dominant-negative Stat5a/b) 
triggered extensive apoptosis across multiple Stat5a/b-
positive PC cell lines. Mechanistically, Stat5a/b was found 
to sustain viability and promote cell cycle progression 
of PC cells through activation of Bcl-xL and cyclin D1, 
respectively [171]. Based on gene array analyses, target 
genes regulated by Stat5a/b include genes regulating 
proliferation, apoptosis and metastatic processes [169, 
170]. These results also translated to the in vivo setting, 
with inhibition of Stat5a/b decreasing the incidence and 
growth of both subcutaneous and orthotopic PC xenograft 
tumors in nude mice [171]. Most importantly, inhibition of 
Stat5a/b blocked not only primary growth of PC xenograft 
tumors, but also recurrent growth of castrate-resistant 
tumors [177] demonstrated by pharmacological inhibition 
of Stat5a/b signaling by a potent Jak2 kinase inhibitor, 
AZD1480, in the CWR22Pc model of CRPC growth. 
In fact, Stat5a/b inhibition was more efficacious than 
docetaxel chemotherapy at both preventing recurrence of 
castrate-resistant CWR22Pc tumors following androgen 
deprivation as well as suppressing growth of established 
castrate-resistant CWR22Pc tumors [177]. 
Stat5a/b induces metastatic behavior and stem-
like cell properties of prostate cancer cells
The first evidence of Stat5a/b promotion of 
metastatic behavior of PC cells in vitro and in vivo [169] 
was provided using an experimental lung metastasis 
model; inoculation of nude mice with PC cells expressing 
an active Stat5 construct (Stat5aS710F) increased in 
vivo formation of lung metastases by 11-fold compared 
to β-galactosidase (LacZ)-expressing control cells [169]. 
Active Stat5a/b upregulated hallmarks of the epithelial-to-
mesenchymal transition (EMT) that precedes metastasis, 
including enhanced migration, decreased expression of cell 
surface E-cadherin, increased expression of mesenchymal 
markers and heterotypic adhesion of both AR-positive 
and AR-negative PC cells to endothelial cells [169, 201]. 
In conjunction with promotion of EMT, Stat5a/b induced 
stem-like properties in PC cells [201], such as tumor 
sphere formation and expression of the cancer stem cell 
marker Bmi1, a core component of Polycomb-Repressive 
Table 1: Comparison of selected Stat5a/b inhibitors in efficacy of inhibition of Stat5a/b tyrosine phosphorylation 
(pYStat5a/b), as detected by Western blot analysis.
Publication (Fig. of Interest): Inhibitor Name: pYStat5a/b Inhibition (µM):
Nam et al. 2012 (Fig. 2A) E804 10-20
Nelson et al. 2011 (Fig. 2A) Pimozide >10
Elumalai et al. 2015 (Fig. 4C) Stafib-1 (Comp. #17) 10
Müller et al. 2008 (Fig. 3A) Comp. #6 400
Page et al. 2012 (Fig. 2A)
BP-1-107
BP-1-108
SF-1-087
SF-1-088
40
Cumaraswamy et al. 2014 (Fig. 4A) AC-3-019 15
Liao et al. 2015 (Fig. 2F) IST5-002 5
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Complex 1 (PRC1), which overrides cellular senescence 
and promotes self-renewal [202-204]. Mechanistically, 
Stat5a/b regulation of both EMT and cancer stem-like cell 
properties were found to be mediated by Twist1, a well-
characterized EMT transcription factor [205-207]. Indeed, 
genetic knockdown of Twist1 suppressed Stat5a/b-induced 
functional endpoints of EMT, and Stat5a/b-induction of 
stem-like features in PC cells. These findings establish 
Stat5a/b in the promotion of EMT processes and a cancer 
stem-like cell phenotype, which enable the formation 
of distant PC metastases. Pharmacological targeting of 
Stat5a/b may prevent metastatic dissemination of PC.
Stat5a/b induces AR activity in prostate 
cancer cells, but also promotes PC cell growth 
independently of AR
Stat5a/b has been shown to promote AR signaling 
in PC cells (Figure 2). The first paper to report functional 
interaction between Stat5a/b and AR demonstrated 
that active Stat5a/b increased nuclear localization and 
transcriptional activity of AR in PC cells [208]. Moreover, 
Stat5a/b and AR were reported to physically interact in 
PC cells [208]. Follow-up studies implicated Stat5a/b in 
regulating proteasomal degradation of androgen-liganded 
AR in PC cells [209]. Specifically, Stat5a/b was shown 
to physically interact with and sequester AR liganded by 
antiandrogens, including enzalutamide, from trafficking to 
the proteasome [209]. Furthermore, antiandrogen therapy 
induced proteasomal degradation of AR in PC cells, a 
degradative mechanism which can be accelerated by 
disruption of Stat5a/b expression or activation [209]. A 
high-profile study using ChIP-Seq to map genome-wide 
occupancy of AR in clinical CRPC specimens revealed 
that AR binding sites in clinical PCs differed markedly 
from those in human PC cell lines. Importantly, novel AR 
binding sites identified in CRPC patients were strongly 
enriched for Stat, Myc and E2F binding motifs, suggesting 
that genomic repositioning of AR in CRPC may be 
induced by cooperating transcription factors in clinical 
CRPC [210]. Notably, this work also demonstrated that 
physical interaction of Stat5a/b and AR occurs in clinical 
CRPC specimens [210].
Importantly, Stat5a/b blockade, by either genetic 
or pharmacological knockdown, induces extensive 
apoptotic death of PC cells that do not express AR. 
Specifically, inhibition of Stat5a/b was found to induce 
rapid apoptotic death of DU145 PC cells, which are 
negative for AR expression, providing evidence that 
Stat5a/b sustains viability of PC cells independently of 
AR [170, 211]. At the same time, Stat5a/b overexpression 
in DU145 cells increased colony formation in vitro and 
accelerated xenograft tumor growth in vivo [198]. These 
findings indicate that Stat5a/b acts through mechanisms 
operating independently of AR to promote growth of PC, 
in addition to mechanisms directly impacting AR function. 
Future challenges include identification of the specific 
mechanisms underlying the capability of Stat5a/b to 
maintain and promote viability of PC cells independently 
of AR. Moreover, it will be important to determine if Stat5 
inhibition will be able to induce death of AR-negative cell 
populations in castrate-resistant prostate tumors.
Pharmacological targeting of Stat5a/b as a 
treatment strategy for prostate cancer
Recent studies demonstrate that enzalutamide 
provides a modest improvement in survival in patients 
with PC due to rapid development of resistance [8, 9]. 
Moreover, in a preclinical model, enzalutamide-resistant 
xenograft tumors treated with an experimental third-
generation antiandrogen responded for only eight weeks 
before resistance developed again [212]. A treatment 
strategy that targets both AR and Stat5a/b concurrently 
potentially provides an additive or even synthetic lethal 
approach to kill PC cells as well as decrease the likelihood 
of selection for resistance mechanisms to the new-
generation anti-androgens. 
Pharmacological inhibition of the Stat5a/b signaling 
pathway can be accomplished through blockade at various 
levels, with inhibitors directed against the cytokine/growth 
factor receptor, tyrosine kinase or Stat5a/b itself. Of note, 
highest specificity with least clinical side-effects is likely 
achieved through direct targeting of Stat5 instead of its 
upstream activators. Indeed, past work has shown that 
disruption of Stat5a/b dimerization, transactivation and/
or DNA binding is possible by targeting of the appropriate 
domain(s). Initial approaches utilized a Stat5a/b dominant-
negative mutant lacking the transactivation domain [171, 
174] and a Stat3 decoy phosphotyrosyl peptide [213, 
214] to demonstrate proof-of-principle of direct Stat 
transcription factor inhibition. More recent investigations 
have shown that natural or synthetic small molecule 
compounds are capable of inhibiting Stat5a/b activity and 
downstream signaling (Table 1).
Compounds which are currently in clinical use for 
a variety of oncologic and non-oncologic indications have 
been found to inhibit Stat5a/b in several preclinical studies 
(Table 1). Nam and colleagues screened a number of 
indirubicin derivatives, demonstrating that the most potent 
compound (E804) blocked Stat5a/b phosphorylation 
at 10-20 µmol/L in K562 human chronic myelogenous 
leukemia (CML) cells positive for Bcr-Abl, which drives 
constitutive activation of Stat5a/b [215]. Pimozide 
(Orap®), an antipsychotic drug, was shown to inhibit Stat5 
phosphorylation in K562 cells by 35-55% at 10 µmol/L 
[216]. Other investigators have pursued rational drug 
design strategies in development of Stat5a/b inhibitors 
(Table 1). Elumalai and colleagues used fosfosal, a 
salicylic acid derivative and previously identified inhibitor 
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of Stat5b [217], as a lead compound for optimization 
studies targeting the Stat5b SH2 domain [218]. The most 
promising compound, known as #17 or Stafib-1 (Stat five b 
inhibitor-1), specifically inhibited Stat5b phosphorylation 
in K562 cells at an IC
50
 of approximately 10 μmol/L [218]. 
In another study, a lead compound identified from a 17,000 
molecule library was modified with chemical substitutions 
to yield a family of Stat5a/b small molecule inhibitors, of 
which compound #6 blocked IFN-α-stimulated Stat5a/b 
phosphorylation in human Burkitt’s lymphoma B cells at 
approximately 400 µmol/L [219]. A different investigator 
group generated a series of SH2-domain binding, salicylic 
acid-derived Stat5a/b inhibitors (BP-1-107, BP-1-108, 
SF-1-087, SF-1-088), which were all capable of fully 
blocking Stat5a/b phosphorylation at 40 µmol/L [220]. 
Building on this work, the investigators used one of their 
previously identified Stat5a/b inhibitors as a scaffold for 
further optimization [221]. A new library of 24 compounds 
was generated, of which AC-3-019 emerged as the most 
promising candidate, inhibiting Stat5a/b phosphorylation 
at 15 µmol/L in K562 cells [221].
Recently, the Nevalainen group identified and 
validated a small molecule inhibitor which targets the 
Stat5a/b SH2 domain in both PC and CML, malignancies 
known to be driven by Stat5a/b signaling [211]. In silico 
screening of chemical structure databases and medicinal 
chemistry modeling yielded 30 top-ranked candidate 
molecules, of which the lead compound IST5-002 proved 
most potent in biological assays [211]. Specifically, IST5-
002 blocked transient docking of the SH2-domain of the 
Stat5 monomer to the phosphotyrosyl moiety of a tyrosine 
kinase-receptor complex, resulting in inhibition of both 
Jak2 and Bcr-Abl-mediated phosphorylation of Stat5. 
Secondly, dimerization of Stat5 was inhibited by IST5-002, 
which may be caused by decreased Stat5 phosphorylation 
or additional suppression of binding of the phosphorylated 
Stat5 monomer to the pY694/699 residues of the partner 
Stat5 monomer. Nuclear translocation, DNA binding 
and transcriptional activity of Stat5 were all inhibited 
at considerably low IC
50
 values, while IL-6-stimulated 
transcriptional activation of Stat3 was unaffected [211]. 
IST5-002 triggered extensive apoptosis of PC cells in 
culture, suppressed growth of PC xenograft tumors in nude 
mice and induced death of patient-derived PCs in ex vivo 
organ cultures [211]. IST5-002 also triggered apoptosis 
of both imatinib-sensitive and imatinib-resistant CML 
cell lines and induced death of primary CML cells [211]. 
Importantly, IST5-002 inhibited Bcr-Abl-driven Stat5a/b 
phosphorylation in K562 cells at an IC
50
 of less than 5 µM 
and, thus, IST5-002 is more potent in cell-based assays 
than any existing published Stat5a/b inhibitors (Table 1). 
Moreover, IST5-002 is the first small molecule inhibitor of 
Stat5a/b to demonstrate efficacy in experimental models of 
solid and hematological malignancies at low micromolar 
potency, providing a highly attractive lead structure for 
further optimization and clinical development.
CONCLUSIONS
PC remains a leading cause of cancer-related death 
for American men, with a subset of patients progressing to 
metastatic CRPC despite receiving aggressive treatment 
for localized cancer. An improved understanding of the 
molecular biology driving cancer progression has allowed 
substantial expansion of the therapeutic landscape for 
CRPC. Over the past five years, a diverse array of novel 
agents has been approved by the FDA for use in CRPC, 
with many other experimental therapies now in late-
stage clinical trials. Most notable in the newly expanded 
treatment options for CRPC are the androgen synthesis 
inhibitor abiraterone and second-generation antiandrogen 
enzalutamide, both of which have been widely adopted 
in clinical practice by medical oncologists. However, 
additional studies are required to optimally integrate these 
new and emerging therapies with existing standard-of-
care treatment paradigms. In addition, drug sequencing 
strategies need to be designed to anticipate and overcome 
newly described resistance mechanisms. Despite the 
impressive progress to date, the lack of a curative therapy 
for CRPC underscores a remaining unmet need, which 
stems from the still incompletely understood transition 
from androgen-dependence to castrate-resistance.
Identification of therapeutic targets which regulate 
non-AR-mediated proliferation and survival pathways 
represent an opportunity to improve treatment for 
advanced PC. Stat5a/b has been previously validated as 
a biomarker and therapeutic target in PC. Active Stat5a/b 
expression levels carry prognostic value by identifying 
patients at risk for cancer recurrence and poor clinical 
outcomes. Levels of active Stat5a/b carry predictive value 
as well, serving to predict treatment response to radical 
prostatectomy in patients with early stage PC. There is a 
strong rationale for pharmacological targeting of Stat5a/b 
based on its pleiotropic effects on sustaining PC growth 
and viability, enhancement of AR transcriptional activity 
and promotion of metastatic behavior. Stat5a/b serves not 
only as a critical survival factor for AR-positive but also 
AR-negative PC cells and xenograft tumors, providing 
a means for targeting PC outside of the AR signaling 
axis. The collective findings described in this review 
indicate that Stat5a/b acts through both AR-dependent 
and AR-independent molecular mechanisms, which are 
distinct but not mutually exclusive and therefore hold the 
potential for imposing synthetic lethal effects if blocked 
simultaneously. Pharmacological inhibition of Stat5a/b 
may thus represent a dual strategy to target growth of PC 
and delay onset of resistance to agents targeting AR in PC. 
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